The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study
Abstract
Purpose: An objective of the fifth National Wilms' Tumor Study (NWTS-5) was to evaluate the efficacy of treatment regimens for anaplastic histology Wilms' tumor (AH). Patients and Methods: Prospective single-arm studies were conducted. Patients with stage I AH were treated with vincristine and dactinomycin for 18 weeks. Patients with stages II to IV diffuse AH were treated with vincristine, doxorubicin, cyclophosphamide, and etoposide for 24 weeks plus flank/abdominal radiation. Results: A total of 2,596 patients with Wilms' tumor were enrolled onto NWTS-5, of whom 281 (10.8%) had AH. Four-year event-free survival (EFS) and overall survival (OS) estimates for assessable patients with stage I AH (n = 29) were 69.5% (95% CI, 46.9 to 84.0) and 82.6% (95% CI, 63.1 to 92.4). In comparison, 4-year EFS and OS estimates for patients with stage I favorable histology (FH; n = 473) were 92.4% (95% CI, 89.5 to 94.5) and 98.3% (95% CI, 96.4 to 99.2). Four-year EFS estimates for patients who underwent immediate nephrectomy with stages II (n = 23), III (n = 43), and IV (n = 15) diffuse AH were 82.6% (95% CI, 60.1 to 93.1), 64.7% (95% CI, 48.3 to 77.7), and 33.3% (95% CI, 12.2 to 56.4), respectively. OS was similar to EFS for these groups. There were no local recurrences among patients with stage II AH. Four-year EFS and OS estimates for patients with bilateral AH (n = 29) were 43.8% (95% CI, 24.2 to 61.8) and 55.2% (95% CI, 34.8 to 71.7), respectively. Conclusion: The prognosis for patients with stage I AH is worse than that for patients with stage I FH. Novel treatment strategies are needed to improve outcomes for patients with AH, especially those with stage III to V disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Treatment of Wilms' tumor. Results of the third national Wilms' tumor study
D'angio, G. J., Breslow, N., Beckwith, J. B., Evans, A., Baum, E., Delorimier, A., Fernbach, D., Hrabovsky, E., Jones, B., Kelalis, P., et al. (1989) · Cancer · doi:10.1002/1097-0142(19890715)64:2<349::aid-cncr2820640202>3.0.co;2-q · Cited by 681
Self-citationAnaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
Bardeesy, N., Falkoff, D., Petruzzi, M.-J., Nowak, N., Zabel, B., Adam, M., Aguiar, M. C., Grundy, P., Shows, T., & Pelletier, J. (1994) · Nature Genetics · doi:10.1038/ng0594-91 · Cited by 339
Self-citationGreen, D. M., Breslow, N. E., Beckwith, J. B., Finklestein, J. Z., Grundy, P. E., Thomas, P. R., Kim, T., Shochat, S. J., Haase, G. M., Ritchey, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.237 · Cited by 307
Self-citationFocal Versus Diffuse Anaplasia in Wilms Tumor—New Definitions with Prognostic Significance
de Faria, P. A. S., Beckwith, J. B., Mishra, K., et al. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199608000-00001 · Cited by 230
Self-citationde Kraker, J., Graf, N., van Tinteren, H., Pein, F., Sandstedt, B., Godzinski, J., & Tournade, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17139-0 · Cited by 217
Green, D. M., Beckwith, J. B., Breslow, N. E., de Faria, P. A. S., Moksness, J., Finklestein, J. Z., Grundy, P. E., Thomas, P. R., Kim, T., & Shochat, S. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2126 · Cited by 179
Self-citationAnaplasia in unilateral Wilms' tumor: A report from the National Wilms' Tumor Study Pathology Center
Zuppan, C. W., Beckwith, J. B., & Luckey, D. W. (1988) · Human Pathology · doi:10.1016/s0046-8177(88)80152-7 · Cited by 148
Self-citationClonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
Bardeesy, N. M., Beckwith, J. B., & Pelletier, J. (1995) · PubMed · Cited by 137
Self-citationMutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
Malkin, D. M., Sexsmith, E., Yeger, H., Williams, B. R. G., & Coppes, M. J. (1994) · PubMed · Cited by 104
Self-citation
Cited by
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
“Unfortunately, patients with anaplastic Wilms tumors have not benefited from advances in therapy to the same extent as those with more favorable histology.(44) Neuroblastoma.”
BackgroundThe genetic changes of Wilms tumour
Treger, T. D., Chowdhury, T., Pritchard-Jones, K., & Behjati, S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0112-0 · Cited by 257
Metadata
- Authors
- Dome, J. S., Cotton, C. A., Perlman, E. J., Breslow, N. E., Kalapurakal, J. A., Ritchey, M. L., Grundy, P. E., Malogolowkin, M., Beckwith, J. B., Shamberger, R. C., Haase, G. M., Coppes, M. J., Coccia, P., Kletzel, M., Weetman, R. M., Donaldson, M., Macklis, R. M., & Green, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-05-20
- Volume
- 24
- Issue
- 15
- Pages
- 2352-2358
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157030129
- Cited by
- 348
- References
- 11
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.